Baltimore, MD – Ameritox recently announced the appointment of A. Scott Walton as its next Chief Executive Officer.
Walton comes to Ameritox from LabCorp, where he spent the past four years as the executive in charge of its Esoteric Testing Business and as one of five members of its Executive Committee. He replaces Ancelmo Lopes, who continues on the Ameritox Board of Directors and has been elected Vice Chairman. Lopes will also serve as a Special Advisor to the company Board and senior executives.
“Scott is a terrific choice to be the new CEO of Ameritox,” said Lopes. “Ameritox continues to expand its clinical strengths and services and Scott’s unique mix of corporate experience that includes senior functional roles overseeing licensing, strategic planning, M&A, and information technology, as well as senior operating roles with responsibility for large and diverse businesses, bodes well for our growth vision.”
Walton has more than two decades of experience in developing and growing health care businesses, including his recent leadership of LabCorp’s Esoteric Business Units that saw consistent year-to-year annual growth under his strategic guidance.
“I am delighted to join Ameritox,” Walton said. “Ameritox has a track record of developing industry leading clinical tools to address complex medical conditions, such as chronic pain. I am looking forward to leading the company through a new phase of growth and to serving providers, patients and payers alike.”